Protéomique, Réponse Inflammatoire, Spectrométrie de Masse (PRISM)

Web site

https://www.laboratoire-prism.fr/

Administrative institutions

Université de Lille
CHU Lille
Inserm

Recent Submissions

Spatial analysis of the glioblastoma proteome reveals specific molecular signatures and markers of survival.

Duhamel, Marie; Drelich, L.; Wisztorski, Maxence; et al.
Nature Communications, Nature Publishing Group, 06-11-2022, 13, 6665

Article dans une revue scientifiquefulltext
Mevitem - a phase i/ii of vismodegib + temozolomide vs temozolomide in patients with recurrent/refractory medulloblastoma with sonic hedgehog pathway activation

Frappaz, Didier; Barritault, Marc; Montane, Laure; et al.
Neuro-Oncology, Oxford Academic, 07-04-2021, 23 (11), 1949–1960

Article dans une revue scientifiquefulltext
Prospective validation of a new imaging scorecard to assess leptomeningeal metastasis: a joint eortc btg and rano effort

Le Rhun, Emilie; Devos, Patrick; Winklhofer, Sebastian; et al.
Neuro-Oncology, 14-02-2022

Article dans une revue scientifique
Trabectedin for recurrent who grade 2 or 3 meningioma: a randomized phase 2 study of the eortc brain tumor group (eortc-1320-btg)

Preusser, Matthias; Silvani, Antonio; Le Rhun, Emilie; et al.
Neuro-Oncology, 21-10-2021

Article dans une revue scientifique
Response assessment of meningioma: 1d, 2d and volumetric criteria for treatment response and tumor progression

Huang, Raymond Y.; Unadkat, Prashin; Linda Bi, Wenya; et al.
Neuro-Oncology, 02-08-2018

Article dans une revue scientifique
Angiotensin ii receptor blockers, steroids and radiotherapy in glioblastoma-a randomised multicentre trial (aster trial). An anocef study

Ursu, R.; Thomas, L.; Psimaras, D.; et al.
European journal of cancer (Oxford, England . 1990), 01-02-2019, 109, 129-136

Article dans une revue scientifique
Working plan for the use of patient-reported outcome measures in adults with brain tumours: a response assessment in neuro-oncology (rano) initiative

Dirven, Linda; Armstrong, Terri S.; Blakeley, Jaishri O.; et al.
The Lancet. Oncology, 01-03-2018, 19, E173-E180

Article dans une revue scientifique
Activity of epidermal growth factor tyrosine kinase inhibitors in non-small cell lung carcinoma with refractory leptomeningeal metastases

Flippot, Ronan; Biondani, Pamela; Auclin, Edouard; et al.
Journal of thoracic oncology . official publication of the International Association for the Study of Lung Cancer, 17-05-2019

Article dans une revue scientifique
Hearing response following internal auditory canal decompression in neurofibromatosis type 2

Bonne, Nicolas-Xavier; Risoud, Michael; Hoa, Michael; et al.
Neurosurgery, 19-03-2019

Article dans une revue scientifique
Intrathecal liposomal cytarabine plus systemic therapy versus systemic chemotherapy alone for newly diagnosed leptomeningeal metastasis from breast cancer

Le Rhun, Emilie; Wallet, Jennifer; Mailliez, Audrey; et al.
Neuro-Oncology, 22-10-2019

Article dans une revue scientifique

Protéomique, Réponse Inflammatoire, Spectrométrie de Masse (PRISM) - U1192

Web site

Administrative institutions

Recent Submissions

Spatial analysis of the glioblastoma proteome reveals specific molecular signatures and markers of survival. ﻿

Mevitem - a phase i/ii of vismodegib + temozolomide vs temozolomide in patients with recurrent/refractory medulloblastoma with sonic hedgehog pathway activation ﻿

Prospective validation of a new imaging scorecard to assess leptomeningeal metastasis: a joint eortc btg and rano effort ﻿

Trabectedin for recurrent who grade 2 or 3 meningioma: a randomized phase 2 study of the eortc brain tumor group (eortc-1320-btg) ﻿

Response assessment of meningioma: 1d, 2d and volumetric criteria for treatment response and tumor progression ﻿

Angiotensin ii receptor blockers, steroids and radiotherapy in glioblastoma-a randomised multicentre trial (aster trial). An anocef study ﻿

Working plan for the use of patient-reported outcome measures in adults with brain tumours: a response assessment in neuro-oncology (rano) initiative ﻿

Activity of epidermal growth factor tyrosine kinase inhibitors in non-small cell lung carcinoma with refractory leptomeningeal metastases ﻿

Hearing response following internal auditory canal decompression in neurofibromatosis type 2 ﻿

Intrathecal liposomal cytarabine plus systemic therapy versus systemic chemotherapy alone for newly diagnosed leptomeningeal metastasis from breast cancer ﻿

Spatial analysis of the glioblastoma proteome reveals specific molecular signatures and markers of survival.

Mevitem - a phase i/ii of vismodegib + temozolomide vs temozolomide in patients with recurrent/refractory medulloblastoma with sonic hedgehog pathway activation

Prospective validation of a new imaging scorecard to assess leptomeningeal metastasis: a joint eortc btg and rano effort

Trabectedin for recurrent who grade 2 or 3 meningioma: a randomized phase 2 study of the eortc brain tumor group (eortc-1320-btg)

Response assessment of meningioma: 1d, 2d and volumetric criteria for treatment response and tumor progression

Angiotensin ii receptor blockers, steroids and radiotherapy in glioblastoma-a randomised multicentre trial (aster trial). An anocef study

Working plan for the use of patient-reported outcome measures in adults with brain tumours: a response assessment in neuro-oncology (rano) initiative

Activity of epidermal growth factor tyrosine kinase inhibitors in non-small cell lung carcinoma with refractory leptomeningeal metastases

Hearing response following internal auditory canal decompression in neurofibromatosis type 2

Intrathecal liposomal cytarabine plus systemic therapy versus systemic chemotherapy alone for newly diagnosed leptomeningeal metastasis from breast cancer